From left, Olalekan Oluwole, M.D., MBBS, MPH, Madan Jagasia, MBBS, M.S., Michael Savona, M.D., and patient Dan Einstein discuss the CAR-T immunotherapy treatment that used Einstein’s own re-engineered immune cells to attack cancer cells. Developing tools to predict which patients will have reactions to immunotherapy like Simons’, and how best to treat them, is one of the goals of a five-year partnership around cancer care Vanderbilt and GE Healthcare are announcing today. “GE has played a huge role in the supply chain, industrialization and processes necessary to deliver CAR-T,” Balser said. Academic medical centers develop things that work in their own specific setting, Balser says, but GE offers the potential to scale up. “Industrialization of machine learning around cancer care might be a way of thinking about how we work together,” Balser says.

Source: Forbes January 06, 2019 12:22 UTC